[1]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389-395,429.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
　Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):389-395,429.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
点击复制

Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第6期
页码:
389-395,429
栏目:
论著
出版日期:
2017-12-05

文章信息/Info

Title:
131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials
作者:
赵炎;  王俊起;  沈婕
300192, 天津市第一中心医院核医学科
Author(s):
Zhao Yan;  Wang Junqi;  Shen Jie
Department of Nuclear Medicine, Tianjin First Center Hospital, Tianjin 300192, China
关键词:
格雷夫斯病; Graves眼病; 甲状腺功能亢进症; 碘放射性同位素; 抗甲状腺药物治疗; 随机对照试验; Meta分析
Keywords:
Graves disease; Graves ophthalmopathy; Hyperthyroidism; Iodine radioisotopes; Antithyroid drugs treatment; Randomized controlled trials; Meta-analysis
DOI:
10.3760/cma.j.issn.1673-4114.2017.06.003
摘要:
目的 通过荟萃分析比较131I治疗与抗甲状腺药物治疗对Graves病的临床治疗效果，包括眼病的发生或恶化、甲状腺功能亢进症（甲亢）的治愈率、甲状腺功能减退症（甲减）发生率、复发率和不良反应。方法 以"Graves病"、"放射性碘"、"抗甲状腺药物"、"治疗"等为关键词检索了1990年至2016年在PubMed检索系统、荷兰医学文摘数据库、科学网、中国生物医学文献服务系统（SinoMed）和中国国家知识基础设施（中国知网）等数据库中发表的关于Graves病131I和抗甲状腺药物治疗效果的随机对照试验（RCTs）研究文献，比较131I治疗与抗甲状腺药物治疗对Graves病患者的疗效。采用12.0版Stata软件进行荟萃分析。结果以置信区间95% CIs风险比表示。利用固定效应模型和随机效应模型，根据研究的异质性，进行综合分析。结果 最终纳入了1992年至2015年的17项RCTs，共4024例患者。综合分析结果表明：131I治疗组和抗甲状腺药物治疗组患新眼病率分别为23.3%和16.1%，甲亢的治愈率分别是77.8%和45.6%，甲减发病率分别是19.7%和9.3%，甲亢复发率分别是6.3%和35.0%。131I治疗会增加患者患眼病（RR=1.36，95% CI：[1.04，1.77]；P=0.024）、眼病恶化（RR=1.76，95% CI：[1.30，2.38]；P<0.001）和甲减的风险（RR=1.99，95% CI：[1.34，2.98]；P=0.001）。但是，与抗甲状腺药物治疗相比，131I治疗的甲亢治愈率高（RR=1.66，95% CI：[1.49，1.86]；P<0.001）、复发率低（RR=0.16，95% CI：[0.08，0.33]；P<0.001），且不良反应的发生率相对较低（RR=0.22，95% CI：[0.10，0.49]；P<0.001）。结论 与抗甲状腺药物治疗相比，131I治疗的甲亢治愈率相对较高，复发率相对较低。但是，131I治疗同时也会增加患眼病和甲减的风险。因此，要采取更积极的干预措施，以减少和预防这些合并症的发生。
Abstract:
Objective To compare radioiodine therapy with antithyroid drugs in terms of clinical outcomes using meta-analysis, including development or worsening of ophthalmopathy, hyperthyroid cure rate, hypothyroidism, relapse rate, and adverse events. Methods Randomized controlled trials(RCTs) published in PubMed, Embase, Web of Science, SinoMed, and National Knowledge Infrastructure, China were analyzed. These studies were published between 1990 and 2016. The selected key search terms were as follows:Graves’ disease, radioiodine, and antithyroid drugs. Therapy was systematically reviewed to compare the effects of radioiodine therapy with antithyroid drugs among patients with Graves’ disease. STATA software v.12.0 was used for data analysis. Results were expressed as risk ratio with 95% confidence intervals(CIs). Pooled estimates were determined using fixed-effect model or random-effect model, depending on the heterogeneity among studies. Results A total of 17 RCTs involving 4024 patients satisfied the inclusion criteria; these studies were published between1992 and 2015. Comprehensive analysis and results indicated that the rate of new ophthalmopathy developed in radioiodine therapy group and antithyroid drug group was 23.3% and 16.1%, respectively. Correspondingly, the hyperthyroid cure rate was 77.8% and 45.6%, the hypothyroidism rate was 19.7% and 9.3%, and the hyperthyroid relapse rate was 6.3% and 35.0%, respectively. Results also showed that radioiodine treatment increased the risk of new ophthalmopathy(RR=1.3, 95% CI:[1.04, 1.77]; P=0.024), development or worsening of ophthalmopathy(RR=1.76, 95% CI:[1.30, 2.38]; P<0.001), and hypothyroidism(RR=1.76, 95% CI:[1.30, 2.38]; P<0.001). Furthermore, radioiodine treatment presented a higher hyperthyroid cure rate(RR=1.66, 95% CI:[1.49, 1.86]; P<0.001), lower recurrence rate(RR=0.16, 95% CI:[0.08, 0.33]; P<0.001), and lower incidence of adverse events(RR=0.22, 95% CI:[0.10, 0.49]; P<0.001) than those of antithyroid drugs. Conclusions Radioiodine therapy is associated with a higher hyperthyroid cure rate and lower relapse rate than those of antithyroid drugs. However, this treatment also increases the risk of ophthalmopathy and hypothyroidism. Considering that antithyroid drug treatment can be associated with unsatisfactory control of hyperthyroidism, we recommend radioiodine therapy as treatment option for patients with Graves’ disease.

参考文献/References:

[1] Cooper GS, Stroehla BC. The epidemiologyof autoimmune discase[J]. Autoimmun Rev, 2003, 2(3):119-125. DOI:http://dx.doi.org/10.1016/Sl568-9972(03)00006-5.
[2] Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden[J]. Eur J Endocrinol, 2011, 165(6):899-905. DOI:10.1530/EJE-11-0548.
[3] Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves’ disease[J]. Autoimmun Rev, 2014, 13(4-5):398-402. DOI:10.1016/j.autrev.2014.01.013.
[4] Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States[J]. Thyroid, 1991, 1(2):129-135. DOI:10.1089/thy.1991.1.129.
[5] Solomon B, Glinoer D, Lagasse R, et al. Current trends in the management of Graves’ disease[J]. J Clin Endocrinol Metab, 1990, 70(6):1518-1524. DOI:10.1210/jcem-70-6-1518.
[6] Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy[J]. Arch Intern Med, 1990, l50(5):1098-1101. DOI:10.1001/archinte.1990. 00390170124027.
[7] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J]. Control Clin Trials, 1996, 17(1):1-12. DOI:10.1016/0197-2456(95)00134-4.
[8] Abraham-Nordling M, Wallin G, Träisk F, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine[J]. Eur J Endocrinol, 2010, 163(4):651-657. DOI:10.1530/EJE-10-0475.
[9] Azizi F, Ataie L, Hedayati M, et al. Effect of long-term continuous methimazole treatment of hyperthyroidism:comparison with radioiodine[J]. Eur J Endocrinol, 2005, 152(5):695-701. DOI:10.1530/eje.1.01904.
[10] Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease:prognostic factors and the role of methimazole[J]. J Clin Endocrinol Metab, 1994, 79(2):542-546. DOI:10.1210/jcem.79.2.7913934.
[11] Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy:a prospective study on the incidence of hypothyroidism[J]. Thyroid, 1995, 5(1):7-12. DOI:10.1089/thy.1995.5.7.
[12] Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group[J]. N Engl J Med, 1992, 326(26):1733-1738. DOI:10.1056/NEJM199206253262603.
[13] Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy[J]. N Engl J Med, 1998, 338(2):73-78. DOI:10.1056/NEJM199801083380201.
[14] 赵伟平. 甲状腺功能亢进应用他巴唑和放射性131I治疗的对比评估及分析[J/OL]. 世界最新医学信息文摘(连续型电子期刊), 2015, 15(83):102-103[2017-09-01]. http://new.wanfangdata.com.cn/details/detail.do?_type=perio&id=sjzxyy-e201583074. DOI:10.3969/j.issn.1671-3141.2015.83.074. Zhao WP. Effect comparison of tapazole versus radioiodine therapy in the treatment of patients with Graves hyperthyroidism[J/OL]. World Latest Med Inform, 2015, 15(83):102-103[2017-09-01]. http://new.wanfangdata.com.cn/details/detail.do?_type=perio&id=sjzxyy-e201583074.
[15] 叶惠成. 131I与抗甲状腺药物治疗300例甲亢患者疗效分析[J]. 中国医学工程, 2015, 23(11):163-164. Ye HC. Treatment analysis of 131I and ATD in 300 patients with Graves’ disease. China Med Eng, 2015, 23(11):163-164.
[16] 黄诚, 李玮, 胡斌, 等. 131I与抗甲状腺药物治疗Graves甲亢的疗效评价[J]. 陕西医学杂志, 2009, 38(6):676-677. DOI:10.3969/j.issn.1000-7377.2009.06.013. Huang C, Li W, Hu B, et al. The curative effects of 131I and ATD for patients with Graves hyperthyroidism[J]. Shaanxi Med J, 2009, 38(6):676-677.
[17] 刘艳, 付立武, 魏月芳, 等. 131I与抗甲状腺药物治疗Graves甲亢的疗效评价[J]. 河南科技大学学报(医学版), 2008, 26(4):265-266. DOI:10.3969/j.issn.1672-688X.2008.04.011. Liu Y, Fu LW, Wei YF, et al. Curative effect evaluation of 131I and ATD therapy for patients with Graves’ hyperthyroidism[J]. J Henan Univ Sci Tech(Med Sci), 2008, 26(4):265-266.
[18] 陈丹云, 陈棠华. 131I与抗甲状腺药物治疗儿童Graves病的疗效对照研究[J]. 中华儿科杂志, 2005, 43(7):507-509. DOI:10.3760/j.issn:0578-1310.2005.07.007. Chen DY, Chen TH. Comparison of the effectiveness of 131I and antithyroid drugs in the treatment of Graves’ disease in children[J]. Chin J Pediatr, 2005, 43(7):507-509.
[19] 陶黎莉. 131I与抗甲状腺药物治疗甲亢的疗效比较[J]. 中国现代药物应用, 2015, 9(21):151-152. DOI:10.14164/j.cnki.cn11-5581/r.2015.21.111. Tao LL. Compaison of efficacy of 131I and antithyroid drugs in the treatment of Graves’ disease[J]. Chin J Mod Drug Appl, 2015, 9(21):151-152.
[20] 徐波, 黄辉, 邝继文. 131I与抗甲状腺药物治疗甲亢的疗效比较[J]. 中国热带医学, 2006, 6(11):2041-2042. DOI:10.3969/j.issn.1009-9727.2006.11.067. Xu B, Huang H, Kuang JW. Comparative study on the therapeutic effect of 131I and anti-thyroidism drugs on hyperthyroidism[J]. China Trop Med, 2006, 6(11):2041-2042.
[21] 杨秀真. 131I与抗甲状腺药物治疗甲亢的疗效比较[J]. 中国药师, 2009, 12(9):1283-1284. DOI:10.3969/j.issn.1008-049X.2009.09. 052 Yang XZ. Therapeutic effect comparison of 131I and anti-thyroid drugs on patients with hyperthyroidism[J]. China Pharmacist, 2009, 12(9):1283-1284.
[22] 邓豪余, 梁昌华, 肖敏, 等. 131碘、抗甲状腺药物及手术治疗Graves甲亢的比较[J]. 中国现代医学杂志, 2003, 13(2):24-27. DOI:10.3969/j.issn.1005-8982.2003.02.009. Deng HY, Liang CH, Xiao M, et al. Comparison of 131I, ATD and surgica1 treatment in the Graves hyperthyroidism patients[J]. China J Mod Med, 2003, 13(2):24-27.
[23] 李三喜. 131 I与抗甲状腺药物治疗甲状腺机能亢进症的疗效比较[J]. 西南军区, 2010, 12(6):1051-1052. DOI:10.3969/j.issn.1672-7193. 2010. 06.006. Li SX. Comparison between the curative effects of 131I and antithyroid drugs on hyperthy-roidism[J]. J Mil Surgeon Southwest China, 2010, 12(6):1051-1052.
[24] 葛冉. 131I与抗甲状腺药物在甲状腺机能亢进症治疗中的应用及比较[J]. 吉林医学, 2015, 36(12):2065. DOI:10.3969/j.issn.1004-0412.2015.12.115. Ge R. Effects comparison between the curative effects of 131I and anti-thyroid drugs on hyperthyroidism[J]. Jilin Med J, 2015, 36(12):2065.
[25] Acharya SH, Avenell A, Philip S, et al. Radioiodine therapy(RAI) for Graves’ disease(GD) and the effect on ophthalmopathy:a systematic review[J]. Clin Endocrinol (Oxf), 2008, 69(6):943-950. DOI:10.1111/j.1365-2265.2008.03279.x.
[26] Ren Z, Qin L, Wang JQ, et al. Comparative Efficacy of Four Treatments in Patients with Graves’ Disease:a Network Meta-analysis[J]. Exp Clin Endocrinol Diabetes, 2015, 123(5):317-322. DOI:10.1055/s-0035-1548824.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]苏丹,赵水喜.甲状腺相关眼病的放射治疗进展[J].国际放射医学核医学杂志,2014,38(2):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
　Su Dan,Zhao Shuixi.The development of radiotherapy for thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
[9]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[10]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[11]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[12]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
　DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]

备注/Memo

备注/Memo:
收稿日期:2017-09-02。
通讯作者:沈婕,Email:shenjie_vip@126.com
更新日期/Last Update: 2017-12-05